GeoVax initiates Phase 2 clinical trial for its experimental COVID-19 booster

Shares of GeoVax Labs Inc. GOVX, -1.42% were down 1.4% in trading on Wednesday after the company said it began a Phase 2 clinical trial for its COVID-19 booster candidate. The study is being conducted at City of Hope hospital in Southern California; it is expected to enroll 60 healthy adults who have been previously vaccinated with any of the three authorized COVID-19 vaccines in the U.S. GeoVax's stock is up 3.8% for the year, while the broader S&P 500 SPX, -0.20% has gained 25.4%.